E. N. Nash Smyth

Real world incidence and management of adverse events in patients with HR+, HER2− metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting

P. Ryan, W. Gathirua-Mwangi, K. Sheffield, 2022, Current medical research and opinion.

Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population

D. Mytelka, L. Bowman, A. Teitelbaum, 2013, Journal of medical economics.

Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2– metastatic breast cancer in the United States

R. Parikh, K. Davis, Yu-jing Huang, 2020, Expert review of pharmacoeconomics & outcomes research.